Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers.
Aged
Carcinoma, Endometrioid
/ diagnosis
Cohort Studies
Computer Simulation
DNA Mismatch Repair
/ genetics
DNA Polymerase II
/ genetics
Endometrial Neoplasms
/ diagnosis
Female
Humans
Machine Learning
Microsatellite Instability
Middle Aged
Mutation
/ genetics
Neoplasm Staging
Poly-ADP-Ribose Binding Proteins
/ genetics
Prognosis
Tomography, X-Ray Computed
/ methods
Tumor Suppressor Protein p53
/ metabolism
Uterus
/ diagnostic imaging
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 10 2020
20 10 2020
Historique:
received:
22
03
2020
accepted:
25
08
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
10
2
2021
Statut:
epublish
Résumé
To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor mutational burden-high (TMB-H) endometrial cancers (ECs). Patients who underwent targeted massively parallel sequencing of primary ECs between 2014 and 2018 and preoperative CE-CT were included (n = 150). Molecular subtypes of EC were assigned using DNA polymerase epsilon (POLE) hotspot mutations and immunohistochemistry-based p53 and MMR protein expression. TMB was derived from sequencing, with > 15.5 mutations-per-megabase as a cut-point to define TMB-H tumors. After radiomic feature extraction and selection, radiomic features and clinical variables were processed with the recursive feature elimination random forest classifier. Classification models constructed using the training dataset (n = 105) were then validated on the holdout test dataset (n = 45). Integrated radiomic-clinical classification distinguished MMR-D from copy number (CN)-low-like and CN-high-like ECs with an area under the receiver operating characteristic curve (AUROC) of 0.78 (95% CI 0.58-0.91). The model further differentiated TMB-H from TMB-low (TMB-L) tumors with an AUROC of 0.87 (95% CI 0.73-0.95). Peritumoral-rim radiomic features were most relevant to both classifications (p ≤ 0.044). Radiomic analysis achieved moderate accuracy in identifying MMR-D and TMB-H ECs directly from CE-CT. Radiomics may provide an adjunct tool to molecular profiling, especially given its potential advantage in the setting of intratumor heterogeneity.
Identifiants
pubmed: 33082371
doi: 10.1038/s41598-020-72475-9
pii: 10.1038/s41598-020-72475-9
pmc: PMC7575573
doi:
Substances chimiques
Poly-ADP-Ribose Binding Proteins
0
Tumor Suppressor Protein p53
0
DNA Polymerase II
EC 2.7.7.7
POLE protein, human
EC 2.7.7.7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17769Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Gynecol Oncol. 2019 Jan;152(1):11-19
pubmed: 30415991
Radiology. 2019 Mar;290(3):783-792
pubmed: 30561278
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Nat Rev Cancer. 2018 Aug;18(8):500-510
pubmed: 29777175
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Am J Surg Pathol. 2013 Jun;37(6):874-81
pubmed: 23629444
Gynecol Oncol. 1989 Apr;33(1):68-70
pubmed: 2703169
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Br J Cancer. 2015 Mar 3;112(5):793-801
pubmed: 25675149
Oncology (Williston Park). 2019 Jun 19;33(6):239-42
pubmed: 31219611
Radiology. 2014 Oct;273(1):168-74
pubmed: 24827998
PLoS One. 2018 Nov 2;13(11):e0206108
pubmed: 30388114
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Eur Radiol. 2017 Oct;27(10):4188-4197
pubmed: 27778090
Gynecol Oncol. 2018 Dec;151(3):401-406
pubmed: 30340772
Nat Med. 2019 Jul;25(7):1054-1056
pubmed: 31160815
JAMA Oncol. 2019 Aug 15;:
pubmed: 31415061
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Radiology. 2018 Jan;286(1):307-315
pubmed: 28727543
JCO Precis Oncol. 2019 Aug 15;3:
pubmed: 32914033
Lancet Oncol. 2014 Jun;15(7):e268-78
pubmed: 24872110
Lung Cancer. 2019 Sep;135:1-9
pubmed: 31446979
Thorac Cancer. 2019 Oct;10(10):1904-1912
pubmed: 31414580
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S93-S113
pubmed: 30550486
Breast Cancer Res. 2017 May 18;19(1):57
pubmed: 28521821
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Stud Health Technol Inform. 2002;85:586-92
pubmed: 15458157
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
J Hepatol. 2019 Jun;70(6):1133-1144
pubmed: 30876945
J Natl Compr Canc Netw. 2018 Feb;16(2):201-209
pubmed: 29439179
J Pathol. 2017 Oct;243(2):230-241
pubmed: 28718916
Semin Diagn Pathol. 2010 Nov;27(4):261-73
pubmed: 21309260
Elife. 2017 Jul 21;6:
pubmed: 28731408
Med Phys. 2003 May;30(5):979-85
pubmed: 12773007
Clin Cancer Res. 2017 Aug 1;23(15):4473-4481
pubmed: 28264871
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Gynecol Oncol. 2004 Jan;92(1):10-4
pubmed: 14751131
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6265-73
pubmed: 26578786
Cancer Treat Rep. 1979 Jan;63(1):21-7
pubmed: 369691
Abdom Radiol (NY). 2019 Nov;44(11):3755-3763
pubmed: 31250180
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Mod Pathol. 2010 Jan;23(1):80-92
pubmed: 19855378
Gynecol Oncol Res Pract. 2017 Dec 2;4:19
pubmed: 29214032
Ann Oncol. 2019 Jun 1;30(6):998-1004
pubmed: 30895304
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
Gynecol Oncol. 2011 Feb;120(2):185-8
pubmed: 21075433
J Magn Reson Imaging. 2016 Jul;44(1):122-9
pubmed: 26756416
Trends Cancer. 2016 Dec;2(12):706-712
pubmed: 28741518
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
J Stat Softw. 2011 Mar;39(5):1-13
pubmed: 27065756
IEEE Trans Pattern Anal Mach Intell. 2005 Aug;27(8):1226-38
pubmed: 16119262
Med Phys. 2018 Jun 13;:
pubmed: 29896896
JAMA Netw Open. 2019 Apr 5;2(4):e192561
pubmed: 31002322
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Am J Surg Pathol. 2009 Jun;33(6):925-33
pubmed: 19238076
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
J Clin Med. 2019 Apr 24;8(4):
pubmed: 31022981
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
Sci Rep. 2019 Sep 17;9(1):13455
pubmed: 31530839
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821